Fresenius Medical Care (FMS) Given a $62.00 Price Target at SunTrust Banks

Fresenius Medical Care (NYSE:FMS) has been given a $62.00 price target by equities researchers at SunTrust Banks in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the stock. SunTrust Banks’ price objective indicates a potential upside of 19.21% from the stock’s previous close.

Several other research analysts have also recently issued reports on FMS. Royal Bank of Canada restated a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care in a report on Wednesday, September 13th. Zacks Investment Research cut shares of Fresenius Medical Care from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care in a report on Monday, November 13th. Finally, Morgan Stanley cut shares of Fresenius Medical Care from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.00.

Fresenius Medical Care (NYSE FMS) opened at $52.01 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. Fresenius Medical Care has a fifty-two week low of $39.46 and a fifty-two week high of $52.41. The stock has a market cap of $31,883.55, a P/E ratio of 23.28, a PEG ratio of 2.33 and a beta of 0.45.

Several institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. grew its holdings in shares of Fresenius Medical Care by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after purchasing an additional 81 shares during the last quarter. Sawtooth Solutions LLC boosted its holdings in Fresenius Medical Care by 2.9% in the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock valued at $236,000 after acquiring an additional 137 shares in the last quarter. BB&T Securities LLC boosted its holdings in Fresenius Medical Care by 1.4% in the second quarter. BB&T Securities LLC now owns 15,053 shares of the company’s stock valued at $727,000 after acquiring an additional 211 shares in the last quarter. Blair William & Co. IL boosted its holdings in Fresenius Medical Care by 2.0% in the second quarter. Blair William & Co. IL now owns 13,638 shares of the company’s stock valued at $659,000 after acquiring an additional 264 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in Fresenius Medical Care by 4.0% in the second quarter. Advisor Group Inc. now owns 8,168 shares of the company’s stock valued at $393,000 after acquiring an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 3.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fresenius Medical Care (FMS) Given a $62.00 Price Target at SunTrust Banks” was first published by American Market News and is owned by of American Market News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/22/fresenius-medical-care-fms-given-a-62-00-price-target-at-suntrust-banks.html.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.